GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » YoY EBITDA Growth

Predilife (XPAR:ALPRE) YoY EBITDA Growth : -15.71% (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Predilife YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Predilife's YoY EBITDA Growth for the quarter that ended in Jun. 2023 was -15.71%.

Predilife's EBITDA per Share for the six months ended in Jun. 2023 was €-0.49.

Predilife YoY EBITDA Growth Historical Data

The historical data trend for Predilife's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife YoY EBITDA Growth Chart

Predilife Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EBITDA Growth
Get a 7-Day Free Trial -42.79 11.20 13.35 -36.23 -

Predilife Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -82.35 -13.21 24.73 -25.71 -15.71

Predilife YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Predilife's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EBITDA Growth (A: Dec. 2022 )
=(EBITDA per Share (A: Dec. 2022 )-EBITDA per Share (A: Dec. 2021 ))/ | EBITDA per Share (A: Dec. 2021 ) |
=(-0.955--0.955)/ | -0.955 |
=0.00 %

Predilife's YoY EBITDA Growth for the quarter that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (Q: Jun. 2023 )
=(EBITDA per Share (Q: Jun. 2023 )-EBITDA per Share (Q: Jun. 2022 )) / | EBITDA per Share (Q: Jun. 2022 )) |
=(-0.486--0.42)/ | -0.42 |
=-15.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Predilife YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Predilife's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Predilife (XPAR:ALPRE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » YoY EBITDA Growth
Comparable Companies
XPAR:GV TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN LH DGX WAT XPAR:BIM EXAS RVTY XPAR:ERF ASX:SHL CRL
Traded in Other Exchanges
N/A
Address
114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800
Website
https://www.predilife.com
Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines